President Donald Trump announced that agreements have been reached with Eli Lilly and Novo Nordisk to reduce the prices of certain obesity medications in a historic step towards making treatments more affordable.
A joint statement from the two companies announced that, in 2026, the agreements will reduce the prices of GLP-1 drugs for Medicare and Medicaid beneficiaries and will also provide these treatments directly to consumers at a discount through a website called TrumpRx.gov, which the Trump administration plans to launch in January.
According to a senior spokesperson for the Trump Administration, starting doses of upcoming obesity pills from Eli Lilly and Novo Nordisk, pending approvals, will be $149 per month for everyone through Medicare, Medicaid or TrumpRx.
Novo Nordisk’s oral form of its obesity injection Wegovy could hit the market by year-end, while Eli Lilly’s pill orforglipron might launch next year.
Initial doses of existing injections such as Novo’s Wegovy and Lilly’s Zepbound will cost $350 per month on TrumpRX. However, according to another senior administration official, these prices will gradually decrease to $245 per month over a two-year period.
David A. Ricks, Lilly chair and CEO told investors, “Today marks a pivotal moment in U.S. health care policy and a defining milestone for Lilly, made possible through collaboration with the Trump Administration. As we expand access to obesity treatments for more Americans and advance one of the most innovative obesity pipelines, we remain focused on improving outcomes, strengthening the U.S. healthcare system, and contributing to the health of our nation for generations to come.”
“This agreement adds to our established commitment to affordability – from being the first company to cap insulin prices at $35
to launching LillyDirect, the end-to-end digital healthcare experience.”
“The U.S. health care system has evolved in a way that’s unfair to American patients and taxpayers who disproportionately pay a higher share of the costs for developing breakthrough medicines compared to other countries,” Ricks added. “Lilly is in a unique position to work with the U.S. government to rebalance the global system, expand access and lower costs for Americans while also protecting our company’s ability to both innovate and enhance manufacturing capacity to meet the significant demand for our life-saving medicines.”
Medicare will start covering obesity drugs for some patients for the first time starting mid-2026.
By CEO NA Editorial Staff
